Achieve Life Sciences (ACHV)
(Real Time Quote from BATS)
$4.33 USD
-0.01 (-0.23%)
Updated Sep 25, 2024 11:20 AM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Achieve Life Sciences, Inc. [ACHV]
Reports for Purchase
Showing records 1 - 20 ( 34 total )
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline For Smoking Cessation; Reiterate Buy and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
ORCA-3 and ORCA-V1 Top-Line Data Expected in 2Q23; Reiterate Buy and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
ORCA-3 Enrollment Is Now Our Primary Focus; Reiterate Buy and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Initiation of Phase 2 ORCA-V1 of Cytisinicline in Nicotine E-Cigarette Cessation; Reiterate Buy Rating and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Non-Dilutive Grant Awarded for Phase 2 ORCA-V1 Trial; Reiterate Buy Rating and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Looking for Potential FDA Approval of Cytisinicline in early 2024; Reiterate Buy Rating and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Positive Phase 3 ORCA-2 Results of Cytisinicline in Adult Smokers; Reiterate Buy and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Cytisinicline Remains on Track for 2022 Catalysts; Reiterate Buy Rating and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Another ORCA Joins the Pod; Reiterate Buy Rating and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Expecting a Pod of ORCA to Generate Important Positive Catalysts in 2022; Reiterate Buy Rating and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
ORCA-2 Phase 3 Trial Fully Enrolled; Reiterate Buy and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
A Slow Start With ORCA-2 is Now Past; Reiterate Buy and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
RAUORA Published Results Show Potential for Better Outcomes With Cytisinicline; Reiterate Buy and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
We Expect ORCA-2 to Lead to a Positive Readout by YE21; Reiterate Buy and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
RAUORAing With an Alternative to Chantix; Reiterate Buy With a Post Reverse-Split Adjusted PT of $24
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Initiating Coverage With a Buy Rating and $2 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V